Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Holdings Boosted by Ieq Capital LLC

Ieq Capital LLC grew its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 65.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,853 shares of the medical equipment provider’s stock after purchasing an additional 3,904 shares during the period. Ieq Capital LLC’s holdings in Zimmer Biomet were worth $1,041,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Dunhill Financial LLC lifted its stake in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares in the last quarter. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at about $25,000. Ashton Thomas Securities LLC purchased a new stake in shares of Zimmer Biomet in the third quarter worth approximately $28,000. Brooklyn Investment Group acquired a new stake in shares of Zimmer Biomet during the third quarter worth approximately $35,000. Finally, Kentucky Trust Co purchased a new position in Zimmer Biomet during the fourth quarter valued at approximately $39,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James reduced their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Wells Fargo & Company upped their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Barclays reduced their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Finally, JMP Securities restated a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $106.00 on Tuesday. The stock has a market cap of $21.10 billion, a P/E ratio of 23.82, a PEG ratio of 1.95 and a beta of 1.02. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The company’s 50-day simple moving average is $105.85 and its 200 day simple moving average is $107.44.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm posted $2.20 earnings per share. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.